Lausanne, Vaud, Switzerland
Anne Marie de Jonge Schuermans, PhD is a senior biopharmaceutical technical operations executive with over 20 years experience across small and large molecules (MAb, Microbial, ADC, GLP-1, ATMP, Oligonucleotide, RNAi). She has held enterprise-level COO, EVP, and SVP roles with full accountability for global manufacturing, CMC, analytical & pharmaceutical Development, quality, supply chain, ESG, EHS, capital deployment, and large-scale transformation programs. Her deep expertise lies in proactive and strategic oversight of CMC, global manufacturing networks (manufacturing sites producing API, biological drug substance, drug products, medical devices and packaging finished goods), external supply networks, BD&L, M&A, and capital strategy (plant construction projects) supporting multi-billion dollar revenues. Anne Marie is a patient-inspired and results-driven executive who aspires to make a positive impact at all times by leveraging science, operational knowledge and the power of inclusive highly motivated and purpose-driven teams. Her cross-functional career has spanned the entire life cycle of small- and large molecules’ medicines (Pharma/RX, OTC, Generics, Medical Device, innovative Biotech & Biosimilars) in all dosage forms (solids, semi-solids and injectables) in multiple territories including Europe, US, Japan, APAC and the Middle East. As an IMD-certified Board professional who has experience in working with boards of stock-listed and private equity owned companies, she approaches the business from a board- and investor perspective. Anne Marie served as an independent board director of a Nasdaq listed biotech company. Moreover, she invests in biotech companies and is an active board member of the Swiss biotech association. In addition to her executive career in Operations, she pursues her passions for corporate sustainability, corporate philanthropy, biotech, neuroscience and entrepreneurship a/o by volunteering as a mentor and advisor.
Senior Vice President with E2E responsibility for the internal- and external manufacturing (CMO’s) and manufacturing supply network of Biologics (mammalians, microbials, oligonucleotides, peptides) and Injectables, incl. oversight of network strategy and investment projects.
Senior Vice President with cross-functional end-to-end responsibility for Global External Manufacturing, Supply, Sourcing & Quality release of API/ DS, Drug Product (DP) and Finished Good (FG, FDP) from CMO/CDMO
As board members of the Swiss Biotech Association, we work on fostering favorable conditions, facilitate access to talent, novel technology and resources. Strengthen and promote the Swiss biotech industry. CMC pillar lead
Independent board director of biopharmaceutical company Pharvaris. Member of the Audit Committee and the Governance Committee
Independent consultant supporting various clients ranging from Private Equity firms to privately held Venture Capital backed Biotech companies with M&A Operational Due Diligence, CMC- and Manufacturing Strategy as well ESG/Sustainability advisory for Boards
Executive Vice President (EVP) and executive committee member with responsibility for Technical & Analytical Development, CMC regulatory, Internal Biologics Manufacturing (commercial and pilot plant), External Manufacturing of Drug Substance, Drug Product and Finished Products, Partnerships, clinical and Commercial Supply Chain (Planning, Logistics, Distribution, Trade Compliance), Direct and Indirect Procurement, ESG, Sustainable sourcing, Quality Assurance & Control, Operational excellence, Engineering, Environment, Health & Safety Operations, Facility Management and Real Estate.